NF-κB in cancer: from innocent bystander to major culprit

By M. Karin, Yixue Cao, F. Greten, Zhi-wei Li. Nature Reviews. Cancer, 2002

2,450 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/d09ffc1051748481fca1136df671b4cf7391b062

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Sebastian M. B. Nijman
2. A. Dirac
3. T. Brummelkamp
4. René Bernards
5. J. Hong
6. M. Park
7. R. Jove
8. Hua Yu

In Immunology

1. M. Karin
2. J. Hong
3. M. Park
4. Alexandru Almasan
5. Simone Fulda
6. Hua Yu
7. K. Debatin
8. R. Jove

In Oncology

1. M. Karin
2. Hua Yu
3. D. Pardoll
4. R. Jove
5. J. Hong
6. M. Park
7. René Bernards
8. T. Brummelkamp

Citations in the corpus

• Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches (2016, background): “The nuclear factor-κB (NF-κB) family of transcription factors control the expression of genes involved in many critical physiological responses such as inflammatory responses, proliferation, differentiation, cell adhesion and apoptosis [1].”
• The NF-κB pathway (2005, background): “Since NF- B also regulates the expression of a variety of proteins that inhibit apoptosis and promote cell survival/proliferation, it is also implicated in carcinogenesis (Karin et al., 2002).”
• The Role of Metallothionein in Oxidative Stress (2013, background): “Overexpression of NF-κB renders cancer cells resistant to chemotherapeutic agents [128,129], and it has been suggested that the antiapoptotic proteins IAP, IEX-1L and the Bcl-2 family are regulated by NF-κB transcription [130–132].”
• Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. (2003, background): “[77] Karin M, Cao Y, Greten FR, Li ZW.”
• Molecular mechanisms of drug resistance (2005, background): “NF-κB has been connected with multiple pathways involved in oncogenesis, including cell cycle regulation and apoptosis [243,244].”
• Integrative genomic approaches identify IKBKE as a breast cancer oncogene. (2007, background): “Since several members of the canonical NF-kB signaling pathway are altered in human leukemia and lymphomas (Karin et al., 2002), these findings indicate that NF-kB activation may occur by distinct mechanisms in different tumor types.”
• Persistently-activated Stat3 maintains constitutive NF-κB activity in tumors (2009, positive): “NF-kB consists of five Rel-related proteins, and the prototypical NF-kB complex is a RelA/p50 heterodimer, which is important for NF-kB-mediated antiapoptotic effects (Karin et al., 2002).”
• Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy (2006, background): “…stress-inducible molecules, for example, c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated protein kinase (ERK), nuclear factor kappa B (NF-kB) or ceramide, have been implied in transmitting the apoptotic signal (Davis, 2000; Karin et al., 2002).”